Breckenridge secures marketing agreement with Gland Pharma for 7 injectables
Breckenridge Pharmaceutical has entered into a multi-product marketing agreement with development and manufacturing partner Gland Pharma Limited for seven injectable products.
Per the agreement, Breckenridge will market and distribute six approved ANDAs and one tentatively-approved ANDA under its label in the United States.
Breckenridge announced its entry into the injectable market in November with the launch of Methylergonovine Maleate Injection. The company commented at the time that the launch was “the first of several planned injectable products” expected in the near future.
The company also announced a license to market Armodafinil tablets – a generic version of Nuvigil® by Cephalon – in partnership with Natco Pharma Limited.
